Abstract
There is evidence that sodium-glucose co-transporter 2 (SGLT2) inhibitors, reduce heart failure (HF) events and cardiovascular (CV) death in cohorts of HF, type 2 diabetes mellitus (T2DM), and those with chronic kidney disease (CKD). These beneficial effects appear to be consistent in patients with varying combinations of these diseases. SGLT2 inhibitors were also found to reduce the risks of clinical events in patients with HF, with early and sustained benefits regardless of ejection fraction and care setting. The clinicians have to be familiar with SGLT2 inhibitors because they are an important component of the modern foundational therapy of HF in order to implement their use and limit the potential adverse effects. This review aims to highlight the current evidence as a practical guide for the prescription of SGLT2 inhibitors in patients with HF, with reference to patient selection, initiation of treatment, and dosing.
| Original language | English |
|---|---|
| Title of host publication | Pathophysiology, Risk Factors, and Management of Chronic Heart Failure |
| Publisher | Elsevier |
| Pages | 377-388 |
| Number of pages | 12 |
| ISBN (Electronic) | 9780128229729 |
| ISBN (Print) | 9780128231111 |
| DOIs | |
| State | Published - 1 Jan 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cardiac hypertrophy
- Cardiovascular outcome trials
- SGLT2 inhibitors
- chronic heart failure
- clinical practical guide
Fingerprint
Dive into the research topics of 'Sodium glucose transporters inhibitors in the management of heart failure'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver